spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Shire PLC  

 HSMN NewsFeed - 21 Jul 2021
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
Biopharmaceutical Neurology Product Launch
 HSMN NewsFeed - 15 Jun 2021
Senda Biosciences Strengthens Leadership Team with Key Management Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 4 Apr 2018
Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 3 Oct 2017
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2017
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2017
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 16 Mar 2017
Shire Receives European Approval for Label Extension of CINRYZE(R) (C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2016
Kamada Announces Extension of GLASSIA(R) Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020
Biopharmaceuticals Distribution Licensing
 HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jul 2016
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2016
FDA Approves Shire’s Xiidra(TM) (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 29 Mar 2016
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Mar 2016
Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2016
Global Blood Therapeutics Announces Changes to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Feb 2015
Shire Acquires Meritage Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Feb 2015
PerkinElmer Elects Sylvie Grégoire to its Board of Directors
Devices Personnel
 HSMN NewsFeed - 29 Dec 2014
BioTime Appoints Adi Mohanty Chief Operating Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2014
Interim Chief Financial Officer James Bowling to Step Down
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2014
Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 19 May 2014
Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2014
Susan Kilsby to Succeed Matthew Emmens as Chairman of Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2014
Organogenesis Inc. Announces Acquisition of Dermagraft(R) from Shire
Devices Wound Care Acquisitions
 HSMN NewsFeed - 17 Jan 2014
Shire Executes Agreement to Divest DERMAGRAFT(R)
Devices Wound Care Acquisitions
 HSMN NewsFeed - 11 Dec 2013
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Sep 2013
InVivo Therapeutics Appoints Gregory D. Perry as Interim CFO
Devices Neurosurgery Personnel
 HSMN NewsFeed - 14 May 2013
Third Rock Ventures Expands and Strengthens Team
Biopharmaceuticals Devices Venture Capital Personnel
 HSMN NewsFeed - 12 Mar 2013
Shire Acquires Premacure AB
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 15 Nov 2012
Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 15 Oct 2012
Promedior Expands Series D Round of Financing to Total $24.5 Million to Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 Sep 2012
DERMAGRAFT(R) Approved in Canada for Treatment of Diabetic Foot Ulcers
Devices Wound Care Regulatory
 HSMN NewsFeed - 20 Mar 2012
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 10 Jan 2012
Shire Acquires US Rights to Resolor(R) (prucalopride)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Nov 2011
Shire Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
Biopharmaceuticals
 HSMN NewsFeed - 6 Apr 2011
Shire Files Lawsuit Against Watson Pharmaceuticals, Inc. for Infringement of ADDERALL XR(R) Patents and for Breach of Contract
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Mar 2011
Data Presented at AAAAI Annual Meeting Further Support the Safety and Efficacy of FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2010
Shire Files Suit Against Impax and Watson
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Jul 2010
Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Apr 2010
INTUNIV(TM) - Shire Files Suit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Feb 2010
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2009
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Oct 2009
FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2009
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2009
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2009
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2009
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2009
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 31 Mar 2009
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2009
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2009
Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 16 Mar 2009
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Mar 2009
Shire Announces Launch of FOSRENOL(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2009
Shire Announces Opening of Office in Japan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Feb 2009
Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
Biopharmaceuticals Generics
 HSMN NewsFeed - 11 Dec 2008
Algeta Appoints Andrew Kay as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2008
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2008
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2008
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Shire Announces Further Expansion Into Latin America
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jan 2008
Noven Announces Changes to Board of Directors and Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2007
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 14 Dec 2007
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2007
David Mott Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2007
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2007
Shire Voluntarily Withdraws a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jul 2007
Shire's New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2007
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2007
Noven & Shire to Develop New Transdermal Patch For ADHD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 20 Jun 2007
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 May 2007
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
Shire Completes Acquisition of New River
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Shire Successfully Completes Tender Offer for New River Shares
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2007
Shire Begins External Search for President of Successful Human Genetic Therapies Business, on Retirement of David Pendergast at the End of 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Oct 2006
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Positive Study Results for DAYTRANA(TM) (methylphenidate transdermal system) Presented at a Major Medical Meeting
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
Shire PLC
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.